ELVN logo

Enliven Therapeutics, Inc. (ELVN) Cash From Investing

Annual CFI:

-$36.00M+$112.42M(+75.75%)
December 31, 2024

Summary

  • As of today, ELVN annual cash from investing is -$36.00 million, with the most recent change of +$112.42 million (+75.75%) on December 31, 2024.
  • During the last 3 years, ELVN annual cash from investing has fallen by -$35.81 million (-18746.60%).
  • ELVN annual cash from investing is now -147.05% below its all-time high of $76.52 million, reached on December 31, 2022.

Performance

ELVN Cash From Investing Chart

Add series to chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Highlights

Range

Earnings dates

OtherELVNcash flow metrics

Quarterly CFI:

-$4.06M+$179.53M(+97.79%)
September 30, 2025

Summary

  • As of today, ELVN quarterly cash from investing is -$4.06 million, with the most recent change of +$179.53 million (+97.79%) on September 30, 2025.
  • Over the past year, ELVN quarterly cash from investing has dropped by -$18.88 million (-127.37%).
  • ELVN quarterly cash from investing is now -105.27% below its all-time high of $77.03 million, reached on December 31, 2022.

Performance

ELVN Quarterly Cash From Investing Chart

Add series to chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Highlights

Range

Earnings dates

OtherELVNcash flow metrics

TTM CFI:

-$185.49M-$18.88M(-11.33%)
September 30, 2025

Summary

  • As of today, ELVN TTM cash from investing is -$185.49 million, with the most recent change of -$18.88 million (-11.33%) on September 30, 2025.
  • Over the past year, ELVN TTM cash from investing has dropped by -$187.46 million (-9554.28%).
  • ELVN TTM cash from investing is now -341.91% below its all-time high of $76.68 million, reached on March 31, 2023.

Performance

ELVN TTM Cash From Investing Chart

Add series to chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Highlights

Range

Earnings dates

OtherELVNcash flow metrics

Cash From Investing Formula

CFI = Cash Inflows from Investments − Cash Outflows for Investments

ELVN Cash From Investing Trends

PeriodPeriodAnnualAnnualQuarterlyQuarterlyTTMTTM
1Y1 Year+75.8%-127.4%-9554.3%
3Y3 Years-10000.0%-10000.0%-1136.5%
5Y5 Years-49.6%+60.5%-389.0%

ELVN Cash From Investing Highs & Lows

PeriodPeriodAnnual vs HighAnnual vs HighAnnual vs LowAnnual vs LowQuarter. vs HighQuarter. vs HighQuarter. vs LowQuarter. vs LowTTM vs HighTTM vs HighTTM vs LowTTM vs Low
3Y3-Year-147.1%+75.8%-105.3%+97.8%-341.9%at low
5Y5-Year-147.1%+75.8%-105.3%+97.8%-341.9%at low
All-TimeAll-Time-147.1%+75.8%-105.3%+97.8%-341.9%at low

ELVN Cash From Investing History

DateAnnualQuarterlyTTM
Sep 2025
-
-$4.06M(+97.8%)
-$185.49M(-11.3%)
Jun 2025
-
-$183.59M(>-9900.0%)
-$166.61M(-898.6%)
Mar 2025
-
$1.43M(+96.3%)
-$16.68M(+53.6%)
Dec 2024
-$36.00M(+75.7%)
$727.00K(-95.1%)
-$36.00M(-1934.7%)
Sep 2024
-
$14.83M(+144.0%)
$1.96M(+104.1%)
Jun 2024
-
-$33.66M(-88.2%)
-$48.41M(+70.9%)
Mar 2024
-
-$17.89M(-146.2%)
-$166.27M(-12.0%)
Dec 2023
-$148.41M(-294.0%)
$38.69M(+208.8%)
-$148.41M(-34.8%)
Sep 2023
-
-$35.55M(+76.5%)
-$110.07M(-47.7%)
Jun 2023
-
-$151.52M(>-9900.0%)
-$74.54M(-197.2%)
Mar 2023
-
-$31.00K(-100.0%)
$76.68M(+0.2%)
Dec 2022
$76.52M
$77.03M(>+9900.0%)
$76.52M(+610.0%)
Sep 2022
-
-$14.00K(+95.4%)
-$15.00M(+37.0%)
DateAnnualQuarterlyTTM
Jun 2022
-
-$303.00K(-56.2%)
-$23.82M(-18.3%)
Mar 2022
-
-$194.00K(+98.7%)
-$20.13M(-1133.4%)
Dec 2021
-$191.00K(+98.9%)
-
-
Dec 2021
-
-$14.49M(-64.1%)
-$1.63M(-104.8%)
Sep 2021
-
-$8.83M(-360.7%)
$34.07M(+4.4%)
Jun 2021
-
$3.39M(-81.5%)
$32.62M(+1127.4%)
Mar 2021
-
$18.30M(-13.7%)
-$3.17M(+81.0%)
Dec 2020
-$16.72M(+30.5%)
$21.21M(+306.3%)
-$16.72M(+55.9%)
Sep 2020
-
-$10.28M(+68.3%)
-$37.93M(-37.2%)
Jun 2020
-
-$32.41M(-781.3%)
-$27.65M(-681.3%)
Mar 2020
-
$4.76M
$4.76M
Dec 2019
-$24.06M(>-9900.0%)
-
-
Dec 2018
$0.00(0.0%)
-
-
Dec 2017
$0.00
-
-

FAQ

  • What is Enliven Therapeutics, Inc. annual cash from investing?
  • What is the all-time high annual cash from investing for Enliven Therapeutics, Inc.?
  • What is Enliven Therapeutics, Inc. annual cash from investing year-on-year change?
  • What is Enliven Therapeutics, Inc. quarterly cash from investing?
  • What is the all-time high quarterly cash from investing for Enliven Therapeutics, Inc.?
  • What is Enliven Therapeutics, Inc. quarterly cash from investing year-on-year change?
  • What is Enliven Therapeutics, Inc. TTM cash from investing?
  • What is the all-time high TTM cash from investing for Enliven Therapeutics, Inc.?
  • What is Enliven Therapeutics, Inc. TTM cash from investing year-on-year change?

What is Enliven Therapeutics, Inc. annual cash from investing?

The current annual cash from investing of ELVN is -$36.00M

What is the all-time high annual cash from investing for Enliven Therapeutics, Inc.?

Enliven Therapeutics, Inc. all-time high annual cash from investing is $76.52M

What is Enliven Therapeutics, Inc. annual cash from investing year-on-year change?

Over the past year, ELVN annual cash from investing has changed by +$112.42M (+75.75%)

What is Enliven Therapeutics, Inc. quarterly cash from investing?

The current quarterly cash from investing of ELVN is -$4.06M

What is the all-time high quarterly cash from investing for Enliven Therapeutics, Inc.?

Enliven Therapeutics, Inc. all-time high quarterly cash from investing is $77.03M

What is Enliven Therapeutics, Inc. quarterly cash from investing year-on-year change?

Over the past year, ELVN quarterly cash from investing has changed by -$18.88M (-127.37%)

What is Enliven Therapeutics, Inc. TTM cash from investing?

The current TTM cash from investing of ELVN is -$185.49M

What is the all-time high TTM cash from investing for Enliven Therapeutics, Inc.?

Enliven Therapeutics, Inc. all-time high TTM cash from investing is $76.68M

What is Enliven Therapeutics, Inc. TTM cash from investing year-on-year change?

Over the past year, ELVN TTM cash from investing has changed by -$187.46M (-9554.28%)
On this page